EUCTR2010-023612-14-GB进行中（未招募）1 期
A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0
Clinical Trials and Research Governance0 个研究点目标入组 56 人开始时间: 2012年12月20日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Male or female, aged 13 years or above at last birthday (note that there is no upper age limit for inclusion in this trial)
- •For those aged greater than or equal to 16 years of age at the time of enrolment, participant is willing and, in the opinion of the investigator, able to give informed consent for participation in the trial
- •For those aged 13-15 at the time of enrolment, participant is willing and, in the opinion of the investigator, able to give informed assent, and parent/guardian is willing and able to give informed consent for participation in the trial.
- •Weight = 50kg
- •Diagnosed with Marfan syndrome according to the revised Ghent criteria 1996
- •Dilated aorta (BSA-adjusted aortic root z-score =2 at the aortic sinuses of Valsalva, using the method of Roman et al, or an absolute aortic root dimension >4.0cm at the sinuses of Valsalva measured using either echocardiography or CMR)
- •If the participant is a female of child-bearing potential, they are willing to ensure effective contraception as defined in the contraception policy
- •If the participant is taking ß-blocker therapy, they are willing to stop taking these one week prior to each CMR scan
- •Willing and, in the investigator’s opinion, able to comply with all trial requirements
- •Willing to allow his or her General Practitioner and if appropriate, Consultant, to be informed of his or her participation in the trial and of any clinical findings or issues which may arise
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 6
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 44
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •The potential participant may not enter the trial if ANY of the following apply:
- •Female who is pregnant
- •Female who is planning pregnancy within 6 months of enrolment
- •Female who is breast feeding
- •Previous aortic dissection
- •Previous aortic surgery
- •Bicuspid or unicuspid aortic valve
- •Scheduled elective cardiac or aortic surgery within 6 months of enrolment
- •Definite diagnosis of Loeys-Dietz or Shpritzen-Goldberg syndrome
- •Known bilateral renal artery stenosis or renal artery stenosis to a single functioning kidney
- •History of idiopathic intracranial hypertension
- •Exposure to angiotensin receptor antagonists, angiotensin converting enzyme inhibitors, or medications containing these compounds in the 3 months prior to enrolment in the trial
- •Absolute indication for angiotensin receptor antagonists, angiotensin converting enzyme inhibitors, doxycycline or other antibiotics of the tetracycline class at enrolment
- •Participant has participated in another research study involving an investigational medicinal product or device in the 3 months prior to enrolment
- •Renal impairment of a moderate or severe degree (eGFR <60 mls/min/1.73m2)
- •Hyperkalaemia (>5.1 mmol/L)
- •Significant hepatic impairment (ALT or AST >3 times upper limit of normal)
- •History of allergic reaction or any other clinically significant intolerance to irbesartan or its constituents; other angiotensin receptor blockers / antagonists; angiotensin converting enzyme inhibitors, doxycycline or its constituents, or placebo medications or its constituents
- •Contra-indications to MRI (e.g. implantable cardiac electronic device, claustrophobia, intracranial aneurysm clips and metallic ocular foreign bodies etc.)
- •Participant currently required to take or likely to be required to start, in the 6 months following enrolment, a medicinal product which is known or suspected to interact, to a clinically significant extent, with irbesartan including: potassium supplementation, potassium sparing diuretics, lithium, regular use of antacids containing aluminium magnesium hydroxide
- •Participant currently required to take or likely to be required to start, in the 6 months following enrolment, a medicinal product which is known or suspected to interact, to a clinically significant extent, with doxycycline including ergotamine and methysergide. This includes drugs known to induce the cytochrome P450 system to a clinically significant extent, including but not limited to, carbamazepine, phenytoin, rifampicin, griseofulvin, barbiturates or sulphonylureas.
- •Alcohol dependence
- •Any other significant disease, disorder or circumstance (e.g. terminal illness), which, in the opinion of the Investigator, may either put the participant at risk in the trial, or may introduce significant bias to the trial, or may affect the participant’s ability to participate in the trial
研究者
相似试验
进行中（未招募）
不适用
Investigating the potential health benefits of ergothioneine supplementation for people with metabolic syndromeISRCTN25890011niversity of Leeds108
招募中
2 期
Effect of centhaquine on cardiovascular parameters in patients with hypovolemic shock.CTRI/2023/12/060444Aman Hospital and Research Centre
进行中（未招募）
1 期
A Randomized pilot study to evaluate the safety and efficacy of Cinryze (C1-Esterase Inhibitor (human)) for the treatment of graft rejection in kidney transplant patientsEUCTR2012-000441-12-DEVIROPHARMA Incorporated20
已完成
2 期
Alendronate for the prevention of osteoporosis in ankylosing spondylitisAnkylosing spondylitis.Ankylosing spondylitisIRCT201212206975N3Vice chancellor for research, Tabriz University of Medical Sciences20
进行中（未招募）
不适用
A Randomized, double-blind, placebo-controlled pilot study of KB001 in mechanically-ventilated patients colonized with pseudomonas aeruginosaEUCTR2007-006764-29-FRKaloBios Pharmaceuticals, Inc.